Jan Nolta Lab in the UC Davis Medical Center
Institute for Regenerative Cures - 2014
2014 -Welcome to the Nolta Lab at the University Of California, Davis Medical Center Campus in Sacramento, Institute for Regenerative Cures Building
The UC Davis Institute for Regenerative Cures (IRC) was renovated from an old State Fair building in 2008 with funding from a major facilities grant from the California Institute for Regenerative Medicine (CIRM). Located in Sacramento, the 109,000 square-foot building is the hub for stem cell and regenerative medicine research and clinical trials for investigators on the Sacramento (UCDHS) and Davis campuses. UC Davis has ten ongoing or recently completed stem cell and regenerative medicine clinical trials, with another 18 in the pipeline.
The IRC also performs IND-enabling studies and clinical trials with many academic and industry partners outside of UC Davis. The UC Davis Stem Cell program, directed by Dr. Jan Nolta and housed within the IRC, has everything that partners need for their IND-enabling studies, with approved rates: a state-of-the art 6 suite Good Manufacturing Practices Facility, a shower in barrier humanized mouse facility for safety and efficacy testing of cell and gene therapy products, a vector core, karyotyping core, Stem Cell core, Quality control and quality assurance core, teratoma core, umbilical cord blood collections program, and a regulatory team.
Staff members have extensive experience in stem cell and gene therapy clinical trials. UC Davis is playing a leading role in regenerative medicine, with over 150 faculty members working together in teams focused on turning stem cells into cures.
Nolta Lab focus:
CIRM announces funding for disease team therapy research grants, 3 of the four top scores in the state belonging to UC Davis!
CIRM press release:
Listen to KQED Forum Interview with Jan Nolta and Alan Trounson - July 27, 2012 (60 minutes)
Our laboratory works in translational biology at the GLP, or “good laboratory practice” level, required to take stem cell therapies, gene therapy and tissue repair studies from the bench to the bedside.
Dr. Nolta is Director of the UC Davis Stem Cell Program and Scientific Director of the GMP facility and assists other Principal Investigators with the rules and regulations involved with obtaining approvals from the Recombinant advisory committee (RAC) and the FDA for cellular therapies. She works closely with Dr. Gerhard Bauer, the Director of the Good Manufacturing Practice Facility in the UC Davis Institute for Regenerative Cures.
Basic/translational work in our lab centers around developing stem cell therapies for peripheral vascular disease and other ischemic disorders, and using stem cells to treat neurodegenerative disorders, primarily focusing on Huntington's Disease (HD/ JHD).